<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nodal marginal zone lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nodal marginal zone lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nodal marginal zone lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3031447296"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nodal marginal zone lymphoma (NMZL) is an uncommon subtype of non-Hodgkin lymphoma. NMZL is a primary nodal lymphoma with histologic features identical to lymph nodes involved by extranodal marginal zone lymphoma or splenic marginal zone lymphoma, but without prominent extranodal or splenic disease.</p><p>The epidemiology, pathogenesis, clinical features, pathology, and diagnosis of NMZL will be discussed here. Extranodal marginal zone lymphoma, splenic marginal zone lymphoma, and primary cutaneous marginal zone lymphoma are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4739.html" rel="external">"Primary cutaneous marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p></p><p class="headingAnchor" id="H34171678"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>NMZL is postulated to originate from nodal marginal zone B cells [<a href="#rid1">1</a>]. The pathogenesis is incompletely understood but acquired mutations in oncogenes and tumor suppressor genes are involved. Gene sequencing has revealed recurrent mutations in KMT2D (previously known as MLL2), PTPRD, NOTCH2, and KLF2 [<a href="#rid2">2</a>].</p><p>While some studies have suggested an association between NMZL and infectious and autoimmune disorders, this association is not as well established as it is for extranodal marginal zone lymphoma and splenic marginal zone lymphoma. Epidemiologic studies have identified an association between hepatitis C virus infection and NMZL [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H4066420747"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>NMZL is the least common of the marginal zone lymphomas and accounts for approximately 1 percent of non-Hodgkin lymphomas [<a href="#rid5">5</a>]. The incidence is approximately six cases per million person-years overall and increases from &lt;1 per million for persons &lt;40 years of age to &gt;10 per million for persons &gt;60 years of age [<a href="#rid5">5</a>]. Median age at diagnosis is approximately 70 years. There is a slight male predominance in most series. The incidence is highest among non-Hispanic White individuals and lowest among Black individuals [<a href="#rid5">5</a>].</p><p>Pediatric NMZL is a distinct entity with an excellent prognosis that typically presents with asymptomatic localized disease involving the lymph nodes of the head and neck [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2158643509"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of NMZL is nonspecific and highly variable. Most patients with NMZL present with painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions [<a href="#rid7">7</a>]. Staging studies often demonstrate widely disseminated (stage III or IV) nodal involvement. Up to one-third have tumors &gt;5 cm (ie, bulky disease). Bone marrow is involved in 30 to 60 percent; rarely, circulating tumor cells are seen in the peripheral blood [<a href="#rid8">8-10</a>]. The spleen and other extranodal tissues are not usually involved at presentation; however, spread to these sites may be seen in individuals with widespread nodal disease.</p><p>Despite widespread involvement, most patients with NMZL are asymptomatic at diagnosis. The following are present in a minority of patients [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>B symptoms (ie, fevers, night sweats, or unintentional weight loss) – 10 to 20 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – 25 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia – 10 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase – 12 to 48 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased beta-2 microglobulin – 29 to 45 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal immunoglobulin – 6 to 33 percent</p><p></p><p>Systemic B symptoms and elevations in lactate dehydrogenase should lead to a more detailed investigation for large cell transformation. (See <a class="local">'Histologic transformation'</a> below.)</p><p>While variable, the majority of NMZL appear to be fluorodeoxyglucose (FDG)-avid on positron emission tomography (PET) [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H1868407446"><span class="h1">PATHOLOGIC FEATURES</span><span class="headingEndMark"> — </span>NMZL is a primary nodal lymphoma that is recognized as a distinct entity in both the World Health Organization Classification of Lymphoid Neoplasms, 5<sup>th</sup> Edition [<a href="#rid13">13</a>] and the International Consensus Classification of Lymphoid Neoplasms [<a href="#rid14">14</a>]. The spleen and other extranodal tissues are not usually involved at presentation; however, spread to these sites may be seen in individuals with widespread nodal disease. The cellular morphology and growth pattern vary, and the pathologic features must be interpreted within the context of clinical features.</p><p>Two morphologic types have been described [<a href="#rid15">15,16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cases resembling extranodal marginal zone lymphoma that are characterized by the presence of aggregates of "monocytoid" B cells with abundant pale cytoplasm in a parafollicular, perivascular, and perisinusoidal distribution. These cases do not express immunoglobulin D (IgD) and have an immunophenotype identical to those of extranodal marginal zone lymphoma [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cases resembling splenic marginal zone lymphoma that have infiltrates of tumor cells surrounding reactive-appearing germinal centers with attenuated mantle zones [<a href="#rid17">17</a>]. These cases typically express IgD and lack CD5, CD23, CD43, and cyclin D1. (See  <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma", section on 'Pathologic features'</a>.)</p><p></p><p>Gene sequencing has revealed mutations in several genes that are also recurrently mutated in splenic marginal zone lymphoma including KMT2D (previously known as MLL2), NOTCH2, and KLF2 [<a href="#rid2">2</a>]. PTPRD is mutated in up to 20 percent of NMZL and is not mutated in splenic marginal zone lymphoma. One series also identified BRAF V600E mutations in 4 of 25 nodal marginal zone lymphomas [<a href="#rid18">18</a>], a finding of potential therapeutic importance because of the availability of BRAF inhibitors.</p><p class="headingAnchor" id="H2868327474"><span class="h1">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of NMZL is usually suspected in a patient with painless lymphadenopathy. The diagnosis is best made by excisional lymph node biopsy followed by further evaluation to exclude extranodal marginal zone lymphoma, splenic marginal zone lymphoma, and other entities that resemble NMZL. A directed evaluation of extranodal sites should be performed to exclude primary extranodal disease. This is described in more detail as part of the pretreatment evaluation. (See <a class="local">'Pretreatment evaluation'</a> below.)</p><p>NMZL is a primary nodal lymphoma; the clinical presentation is a key part of making the diagnosis and excluding extranodal marginal zone lymphoma and splenic marginal zone lymphoma. The spleen and other extranodal tissues are not usually involved in NMZL at presentation; however, spread to these sites may be seen in individuals with widespread nodal disease. In some instances, it may be unclear exactly where the disease originated. A diagnosis of NMZL is favored if there is widespread nodal involvement, even in the setting of splenic enlargement and/or minimal extranodal involvement. In contrast, extranodal marginal zone lymphoma is favored when the extranodal involvement is prominent and nodal involvement is localized.</p><p>It is unclear whether marginal zone lymphoma of Waldeyer's ring should be classified as NMZL or extranodal marginal zone lymphoma. The diagnoses of splenic marginal zone lymphoma and extranodal marginal zone lymphoma are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p>The diagnosis of NMZL should <strong>not</strong> be made when areas consistent with another low-grade B cell lymphoma (follicular lymphoma, mantle cell lymphoma) are present in the same node. Most cases with histologic features of both NMZL and another low-grade lymphoma appear to stem from the focal differentiation of another lymphoma (usually follicular lymphoma) to marginal zone B cells or monocytoid B cells. Thus, such cases do not represent true biclonal "composite" lymphomas and should be diagnosed as a single lymphoma (most commonly follicular lymphoma) other than NMZL [<a href="#rid19">19</a>].</p><p>Other B cell neoplasms that may be confused with NMZL include those that are also composed mainly of small B cells  (<a class="graphic graphic_table graphicRef118411" href="/z/d/graphic/118411.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follicular lymphoma (FL)</strong> – NMZL can demonstrate a partially nodular pattern of growth that may resemble FL. NMZL can usually be differentiated from FL by immunophenotype since, unlike FL, marginal zone lymphoma does not usually express CD10 or BCL6. Also, FL is strongly associated with a (14;18) translocation involving the <em>BCL2</em> gene that is not a feature of NMZL. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mantle cell lymphoma (MCL)</strong> – MCL with a mantle zone pattern of growth may superficially resemble NMZL, but can be differentiated in most cases by immunophenotype, as MCL usually expresses CD5, SOX11, and cyclin D1, the latter due to the presence of a (11;14) translocation that is not seen in NMZL. (See  <a class="medical medical_review" href="/z/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)</strong> – CLL/SLL is distinguished by expression of CD5 and by a diffuse growth pattern associated with proliferation centers, a feature that is not seen in NMZL. (See  <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoplasmacytic lymphoma (LPL, also known as Waldenström macroglobulinemia [WM])</strong> – The differentiation between nodal LPL and IgM-secreting NMZL is sometimes difficult as the immunohistochemical features of NMZL and LPL are similar. Although MYD88 mutations are seen in the vast majority of WM, they are not specific; MYD88 mutations can be seen in 5 to 10 percent of patients with NMZL. Clinically, NMZL is more likely to present with prominent lymphadenopathy, while LPL can exclusively affect the marrow without extramedullary involvement. IgM levels in NMZL tend to be lower than in LPL, typically lower than 1000 mg/dL. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="headingAnchor" id="H1359236470"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H73869423"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>The pretreatment evaluation of a patient with NMZL is focused on determining the extent of disease and comorbidities that may impact on choice of therapy. In general, we perform the following examinations:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination with determination of the patient's performance status by the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing includes a complete blood count with differential and platelet count, chemistries with liver and renal function and electrolytes, lactate dehydrogenase, HIV, and hepatitis C virus serology. Patients should also be tested for hepatitis B virus prior to the use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> therapy. Women of childbearing age should undergo a pregnancy test if chemotherapy or radiation therapy is planned.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging should include a contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis. The decision to include positron emission tomography (PET) is individualized. Studies evaluating the use of PET in marginal zone lymphoma have demonstrated variable fluorodeoxyglucose (FDG) avidity, although the sensitivity for detecting nodal involvement is high [<a href="#rid11">11,12,20-24</a>]. Combined PET/CT is more sensitive than CT alone, but false positive exams may be seen. Unlike in some other lymphoma subtypes, FDG PET/CT has a low sensitivity for identifying bone marrow involvement in NMZL. In a series of 61 patients with NMZL of whom 51 percent had pathologically confirmed bone marrow involvement, FDG PET/CT had the following test characteristics for identifying bone marrow involvement: sensitivity 39 percent, specificity 100 percent, positive predictive value 100 percent, negative predictive value 61 percent [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage is determined with the Lugano modifications to the Ann Arbor staging system  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 4</a>). If clinical stage I or II disease is suspected, a bone marrow aspiration and biopsy should be performed to confirm limited disease.</p><p></p><p>In addition, for patients with <strong>localized</strong> nodal involvement, clinicians should have a high degree of suspicion for marginal zone lymphoma of an extranodal primary site that has spread to the lymph nodes:</p><p class="bulletIndent1"><span class="glyph">●</span>Neck node involvement – Evaluate for ocular, parotid, thyroid, and salivary gland marginal zone lymphoma. A more detailed examination may be necessary in patients with Sjögren’s disease or Hashimoto thyroiditis because of the strong association between these disorders and extranodal marginal zone lymphoma [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Axillary node involvement – Evaluate for lung, breast, and skin marginal zone lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal or hilar node involvement – Evaluate for lung marginal zone lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal node involvement – Evaluate for splenic and gastrointestinal marginal zone lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inguinal or iliac node involvement – Evaluate for gastrointestinal and skin marginal zone lymphoma.</p><p></p><p class="headingAnchor" id="H2363855841"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H4209659767"><span class="h3">Goals of therapy</span><span class="headingEndMark"> — </span>Patients with advanced (stage III or IV) NMZL are usually not cured with conventional treatment. While remissions can be attained, repeated relapses are common. Treatment focuses on the alleviation of symptoms, reversal of cytopenias, and improvement of quality of life. As such, asymptomatic patients often do not require immediate treatment but should be followed for the development of symptoms and progression of disease. This approach is similar to that used for other clinically indolent non-Hodgkin lymphomas such as follicular lymphoma. (See  <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Indications for treatment'</a>.)</p><p>An important exception is the minority of patients who present with NMZL confined to a single lymph node or group of adjacent nodes (stage I); such patients may be candidates for radiation therapy administered with curative intent. (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Radiation therapy (RT)'</a>.)</p><p>The prognosis of patients with NMZL is discussed separately. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2818062054"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>There is no single preferred therapy for NMZL, and we encourage patients to participate in trials, whenever possible. Most data come from retrospective studies and extrapolation of data from other common indolent lymphomas, such as follicular lymphoma. While patients with marginal zone lymphoma tend to respond to therapies used for other indolent lymphomas, some studies that have provided data for this subpopulation have noted differences in response rates and other clinically important outcomes, as described below. Until more data are available from trials limited to patients with marginal zone lymphoma, patients with marginal zone lymphoma not on a clinical trial are often treated in a similar fashion to those with the more common indolent lymphoma follicular lymphoma. The treatment of follicular lymphomas is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a>.)</p><p>Our approach differs according to disease and patient factors:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with NMZL limited to a single lymph node region, we suggest radiation therapy administered with curative intent (eg, 24 Gy to the involved site/node). (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Radiation therapy (RT)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of more advanced stage disease usually includes immunotherapy with monoclonal antibodies directed at CD20 (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) with or without chemotherapy. The decision to use combination therapy (ie, chemotherapy plus rituximab) depends on the goals of therapy and patient values [<a href="#rid28">28,29</a>]; the addition of chemotherapy results in deeper responses and prolonged progression-free survival (PFS), but does not improve overall survival (OS) and is associated with increased toxicity.</p><p></p><p class="bulletIndent1">Combination therapy may be preferred by patients who have more severely symptomatic bulky disease and those who place a high value on a longer treatment-free period. Others reserve chemotherapy for relapsed or refractory disease following single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'Incorporation of chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1">Single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be preferred by patients who are more mildly symptomatic and by those who place a high value on the avoidance of the short-term toxicities associated with chemotherapy. (See <a class="local">'Single-agent rituximab'</a> below.)</p><p></p><p class="bulletIndent1">An initial trial of treatment directed at the hepatitis C virus (HCV) infection may be indicated for patients with HCV who are asymptomatic from their lymphoma and would otherwise not require the initiation of lymphoma-direct treatment. A number of reports, primarily from Europe, have described remissions following HCV treatment in some patients with indolent lymphoma, including marginal zone lymphoma [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Patients with hepatitis C'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapsed disease is usually managed with the serial administration of systemic treatments (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, chemotherapy, targeted therapy [eg, BTK inhibitor, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>]). Prolonged disease-free survival (DFS) has been achieved after autologous hematopoietic cell transplantation in select patients. (See <a class="local">'Targeted therapies (BTK inhibitors, lenalidomide)'</a> below and <a class="local">'Hematopoietic cell transplantation'</a> below.)</p><p></p><p class="headingAnchor" id="H2488894167"><span class="h3">Single-agent rituximab</span><span class="headingEndMark"> — </span>Single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be preferred by patients who are more mildly symptomatic and by those who place a high value on the avoidance of the short-term toxicities associated with chemotherapy. It is also an acceptable initial treatment for patients with comorbid conditions that make them poor candidates for combination therapy. Rituximab has a low toxicity profile and has been shown to delay disease progression in these populations.</p><p>Different schedules have been used. The following administration schedules were used in the randomized trials and are equally acceptable approaches:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> 375 mg/m<sup>2</sup> intravenously per week for a total of four doses [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> 375 mg/m<sup>2</sup> intravenously per week for four weeks, followed by four additional doses administered every two months [<a href="#rid28">28,29</a>].</p><p></p><p>Major toxicities with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> include infusion reactions (ie, fevers, rigors, and hypotension) and infections related to immunosuppression. Rare cases of progressive multifocal leukoencephalopathy have been reported. Rituximab imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>Support for the use of immunotherapy in marginal zone lymphoma is based on the extrapolation of a benefit among patients with other lymphomas that express CD20. In addition, an international trial of patients with extranodal marginal zone lymphoma not responding to or not suitable for local therapy randomly assigned treatment to <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid28">28,29</a>]. After completion of the planned accrual, a third arm was incorporated to investigate the use of single-agent rituximab. The entire cohort of 454 patients were followed for a median of 7.4 years with the following results:</p><p class="bulletIndent1"><span class="glyph">●</span>When compared with <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> alone, the combination of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus chlorambucil resulted in improved rates of complete remission (CR; 79 versus 63 percent), event-free survival (EFS) at five years (68 versus 51 percent), and PFS (72 versus 59 percent). Rituximab infusion was associated with infusion-related symptoms in approximately 20 percent, the majority of which were mild (grade 1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When compared with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> alone, the combination of rituximab plus <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> resulted in improved rates of CR (79 versus 56 percent), EFS at five years (68 versus 50 percent), and PFS (72 versus 57 percent). Patients treated with chlorambucil had higher rates of hematologic toxicity, although the absolute numbers were small.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All three arms had a five-year OS of approximately 90 percent.</p><p></p><p>Response rates to single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> are lower than those seen in follicular lymphoma. In the multicenter RESORT trial, 71 patients with low tumor burden previously untreated marginal zone lymphoma received four weekly doses of rituximab [<a href="#rid31">31,32</a>]. Of these, 37 patients (52 percent) achieved a complete or partial response and were randomly assigned to rituximab maintenance or to observation and retreatment with rituximab at the time of progression. Overall response rates differed by subtype: splenic marginal zone lymphoma (5 of 5 patients), NMZL (17 of 28 patients), and extranodal marginal zone lymphoma (15 of 38 patients). This compares to a 73 percent overall response rate among patients with follicular lymphoma in the same trial. While observation was associated with a shorter time to treatment failure and shorter time to first cytotoxic chemotherapy, estimated OS at five years was similar in both groups (90 percent).</p><p class="headingAnchor" id="H40720039"><span class="h3">Incorporation of chemotherapy</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus chemotherapy may be preferred as initial therapy over rituximab alone by patients who have more severely symptomatic bulky disease due to its ability to achieve deeper responses. Others reserve chemotherapy for relapsed or refractory disease following single-agent rituximab. </p><p>The preferred chemotherapy regimen to combine with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is not clearly defined and depends on patient comorbidities and expected toxicities. For most patients, we offer <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> plus rituximab as used for follicular lymphoma. As described above, rituximab can also be combined with <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>. (See <a class="local">'Single-agent rituximab'</a> above.)</p><p>Patients with marginal zone lymphoma have been included in studies of alkylating agent-based regimens such as R-CHOP (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>), R-CVP (cyclophosphamide, vincristine, and <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> plus rituximab), and the combination of <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> plus rituximab (BR). As examples:</p><p>Two randomized trials compared BR versus R-CHOP or R-CVP in patients with indolent lymphoma, including marginal zone lymphoma [<a href="#rid33">33,34</a>]. BR resulted in at least equivalent efficacy and less toxicity. The vast majority of patients receiving BR demonstrated a response, most of which were sustained at five years.</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, phase 3 noninferiority trial comparing BR versus R-CHOP included 67 patients with marginal zone lymphoma [<a href="#rid33">33</a>]. In the patients with other histologic subtypes, BR improved PFS and was less toxic than R-CHOP. Among the patients with marginal zone lymphoma, median PFS with BR was not significantly different from that with R-CHOP (57 versus 47 months; HR 0.70, 95% CI 0.34-1.43).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second randomized, phase 3 study comparing BR versus R-CHOP or R-CVP included 46 patients with marginal zone lymphoma [<a href="#rid34">34,35</a>]. Among the patients with marginal zone lymphoma, BR resulted in similar CR (20 versus 24 percent) and overall (92 versus 71 percent) response rates. BR was associated with higher rates of vomiting and drug hypersensitivity and lower rates of peripheral neuropathy/paresthesia and alopecia. BR improved PFS (66 versus 56 percent at five years; HR 0.61, 95% CI 0.45-0.85) for the group as a whole, a finding which lost statistical significance when the patients with mantle cell lymphoma were removed from the analysis. OS was similar in the two treatment arms (HR 1.15; 95% CI 0.72-1.84).</p><p></p><p>As these trials included a small number of patients with MZL, further support for BR comes from nonrandomized trials and observational studies. In an international retrospective study of BR as initial therapy for 237 patients with extranodal MZL, the estimated five-year PFS and OS were 81 and 90 percent, respectively [<a href="#rid36">36</a>]. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> maintenance was associated with longer PFS, but not OS. Additional details regarding BR for follicular lymphoma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Bendamustine plus rituximab'</a>.)</p><p>While uncommonly used, the combinations of <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">pentostatin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (PCR) and <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> plus rituximab (FR) have also shown activity in nonrandomized phase 2 trials [<a href="#rid37">37-39</a>].</p><p class="headingAnchor" id="H3485646320"><span class="h3">Targeted therapies (BTK inhibitors, lenalidomide)</span><span class="headingEndMark"> — </span>Novel targeted therapies may be of particular importance for patients with progression within 24 months of initial systemic chemotherapy since such patients have worse survival than those with longer initial remissions [<a href="#rid40">40,41</a>]. They also provide a treatment option for multiply relapsed marginal zone lymphoma (MZL). </p><p>Studies have evaluated Bruton tyrosine kinase (BTK) inhibitors (eg, <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">zanubrutinib</a>) and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> in patients with marginal zone lymphoma, although most are significantly limited by the small number of patients with MZL and short follow-up. </p><p>Both <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">zanubrutinib</a> and the combination of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> are approved by the US Food and Drug Administration (FDA) for the treatment of relapsed MZL based on single-arm trial data. While <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> had accelerated approval in this setting based on higher than expected response rates in a single-arm phase 2 trial [<a href="#rid42">42,43</a>], the manufacturer voluntarily withdrew approval for this indication after a confirmatory phase 3 trial evaluating the addition of ibrutinib to chemoimmunotherapy (SELENE, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT01974440%3Ftab%3Dresults&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzat8igw35QrBgYlwb5Kluy3nKW4WCAu%2F1KvwjUqZdNhJ6Uh6U%2FfIUheF%2F9uDuKLIA%3D&amp;TOPIC_ID=113327" target="_blank">NCT01974440</a>) did not meet its primary endpoint of improved progression-free survival [<a href="#rid44">44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zanubrutinib</strong> – Two open-label, single-arm phase 2 trials evaluated <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">zanubrutinib</a> in a total of 86 patients with relapsed MZL (MAGNOLIA, NCT03846427 [<a href="#rid45">45</a>] and BGB-3111-AU-003, NCT02343120 [<a href="#rid46">46</a>]). A response was documented in 68 to 80 percent, with a CR in 17 to 20 percent and a median time to response of approximately 3 months. Estimated PFS rates were 83 to 84 percent at one year and 72 percent at three years. Common toxicities included gastrointestinal toxicity, infections, and bleeding/bruising. Based on these data, zanubrutinib is approved by the FDA for MZL relapsing after at least one anti-CD20-based regimen [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenalidomide</strong><strong> plus </strong><strong>rituximab</strong> – Open-label, phase 2 studies of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> have reported complete responses in 55 to 65 percent of patients with previously untreated MZL [<a href="#rid48">48,49</a>]. However, the efficacy of lenalidomide in this population was questioned when a subgroup analysis of the 63 patients with MZL included in the phase 3 randomized AUGMENT trial evaluating lenalidomide plus rituximab versus placebo plus rituximab in relapsed non-Hodgkin lymphoma did not reveal a PFS benefit (HR 1.00; 95% CI 0.47-2.13) [<a href="#rid50">50</a>]. Lenalidomide plus rituximab is approved by the FDA for previously treated MZL. Further information about administration and toxicity is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma", section on 'Lenalidomide plus rituximab or obinutuzumab'</a>.)</p><p></p><p class="headingAnchor" id="H3548085155"><span class="h3">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>There are limited data regarding the use of high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in NMZL. Small case series suggest that fit patients with chemotherapy-sensitive disease at the time of relapse may achieve long-term disease control. Eligibility for HCT is primarily determined based on the patient's age, their performance status, and/or the presence of comorbid conditions. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p>The largest series included 199 patients undergoing autologous HCT for relapsed, non-transformed marginal zone lymphoma (111 extranodal, 55 nodal, and 33 splenic) between 1994 and 2013, 95 percent of whom had chemotherapy-sensitive disease [<a href="#rid51">51</a>]. Estimated rates of relapse/progression, nonrelapse mortality, second malignancy, and OS at five years were 38, 9, 6, and 73 percent, respectively. The risk of relapse decreased with time from transplant, suggesting that some patients achieve long-term disease control. On multivariate analysis, older age and splenic marginal zone lymphoma subtype were associated with worse survival.</p><p>The high rates of death due to early transplant-related complications in most series are reflective of the study time period [<a href="#rid52">52,53</a>]. Advances in protocols for autologous HCT has resulted in lower nonrelapse mortality rates among patients with non-Hodgkin lymphoma (eg, 2 to 5 percent). Long-term toxicities of autologous HCT include treatment-related myelodysplasia/secondary leukemia, secondary solid tumors, cardiac disease, pulmonary toxicity, and infection. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Autologous HCT'</a>.)</p><p class="headingAnchor" id="H1251536059"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Patients with NMZL are usually not cured with conventional treatment. While remissions can be attained, repeated relapses are common. Five-year OS in various series has ranged from 55 to 80 percent [<a href="#rid10">10,54-58</a>]. Prognostic factors are not well defined. A higher FLIPI (follicular lymphoma international prognostic index) score is associated with worse OS [<a href="#rid10">10,58,59</a>]. At the time of relapse, the duration of initial remission provides a measure of tumor aggressiveness. Patients with progression within 24 months of initial systemic chemotherapy have worse survival than those with longer initial remissions [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Follicular lymphoma IPI (FLIPI)'</a>.)</p><p class="headingAnchor" id="H1497381481"><span class="h1">HISTOLOGIC TRANSFORMATION</span><span class="headingEndMark"> — </span>An integral part of the natural history of all indolent non-Hodgkin lymphomas, including NMZL, is progression to a higher-grade histologic subtype, such as diffuse large B cell lymphoma. Large cell transformation has been reported in up to 15 percent of patients with NMZL; the estimated median time from diagnosis to transformation is 4.5 years (range 1 to 22 years) [<a href="#rid58">58,60,61</a>].</p><p>Large cell transformation should be suspected in patients with systemic B symptoms (eg, fatigue, night sweats, weight loss), elevations in lactate dehydrogenase, and/or rapidly enlarging lymph nodes. If large cell transformation is suspected clinically, a PET scan can help guide biopsy site selection.</p><p>There are little data to guide the selection of therapy in the setting of large cell transformation. We manage large cell transformation in a similar fashion to histologic transformation of follicular lymphoma. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Following histologic transformation'</a>.)</p><p class="headingAnchor" id="H1222025188"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122004.html" rel="external">"Society guideline links: Marginal zone lymphoma"</a>.) </p><p class="headingAnchor" id="H4093949692"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and presentation</strong> – Nodal marginal zone lymphoma (NMZL) is a primary nodal lymphoma with histologic features similar to extranodal marginal zone lymphoma (MZL) or splenic MZL, but with prominent lymph node involvement and less prominent extranodal and splenic involvement. It is rare, comprising approximately 1 percent of non-Hodgkin lymphoma cases. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1">Most patients present with asymptomatic stage III or IV non-bulky nodal disease  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 4</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – NMZL resembles extranodal MZL and splenic MZL morphologically and immunophenotypically. (See <a class="local">'Pathologic features'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of NMZL is made based on nodal biopsy evaluation in the context of the clinical presentation. This diagnosis should be made with caution in patients with a condition that places them at high risk of extranodal marginal zone lymphoma (eg, Sjögren’s disease) and should not be made when another low-grade B cell lymphoma (eg, follicular lymphoma) is present in the same node. (See <a class="local">'Diagnosis and differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Goals of therapy</strong> – Patients with NMZL are usually not cured with conventional treatment. While remissions can be attained, repeated relapses are common. Treatment focuses on the alleviation of symptoms, reversal of cytopenias, and improvement of quality of life. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Encourage clinical trials</strong> – There is no single preferred therapy for NMZL, and we encourage patients to participate in trials whenever possible. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extrapolation of data from other indolent lymphomas</strong> – For patients with NMZL not on a clinical trial, we offer treatment similar to that used for the more common indolent lymphoma, follicular lymphoma (FL)  (<a class="graphic graphic_algorithm graphicRef115334" href="/z/d/graphic/115334.html" rel="external">algorithm 1</a>). Patients with MZL were included in many of the studies that support these treatment recommendations for FL. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent2">For patients with NMZL limited to a single lymph node region, we suggest radiation therapy administered with curative intent rather than observation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Radiation therapy (RT)'</a>.)</p><p></p><p class="bulletIndent2">Patients with more advanced asymptomatic NMZL do not require immediate treatment but should be followed closely. For patients with more advanced, symptomatic NMZL, we offer an anti-CD20 monoclonal antibody (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a>) with or without chemotherapy. The decision to incorporate chemotherapy depends on the goals of therapy and patient values; the addition of chemotherapy results in deeper responses and prolonged progression-free survival but does not improve overall survival and is associated with increased toxicity. (See <a class="local">'Choice of therapy'</a> above.)</p><p></p><p class="bulletIndent2">Relapsed disease is usually managed with the serial administration of systemic treatments (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, chemotherapy, targeted therapy [eg, BTK inhibitor, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>]). Prolonged disease-free survival has been achieved after autologous hematopoietic cell transplantation in select patients. (See <a class="local">'Targeted therapies (BTK inhibitors, lenalidomide)'</a> above and <a class="local">'Hematopoietic cell transplantation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001; 98:781.</a></li><li><a class="nounderline abstract_t">Spina V, Khiabanian H, Messina M, et al. The genetics of nodal marginal zone lymphoma. Blood 2016; 128:1362.</a></li><li><a class="nounderline abstract_t">Xiong W, Lv R, Li H, et al. Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. Blood Cancer J 2017; 7:e548.</a></li><li><a class="nounderline abstract_t">Chuang SS, Liao YL, Chang ST, et al. Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. J Clin Pathol 2010; 63:595.</a></li><li><a class="nounderline abstract_t">Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol 2014; 165:67.</a></li><li><a class="nounderline abstract_t">Taddesse-Heath L, Pittaluga S, Sorbara L, et al. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 2003; 27:522.</a></li><li><a class="nounderline abstract_t">van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 2013; 98:1003.</a></li><li><a class="nounderline abstract_t">Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.</a></li><li><a class="nounderline abstract_t">Carbone A, Gloghini A, Pinto A, et al. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. Am J Clin Pathol 1989; 92:228.</a></li><li><a class="nounderline abstract_t">Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 2007; 136:301.</a></li><li><a class="nounderline abstract_t">Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51:25.</a></li><li><a class="nounderline abstract_t">Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64:336.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Campo E, Miquel R, Krenacs L, et al. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol 1999; 23:59.</a></li><li><a class="nounderline abstract_t">Pillonel V, Juskevicius D, Ng CKY, et al. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. Leukemia 2018; 32:2412.</a></li><li><a class="nounderline abstract_t">Nathwani BN, Anderson JR, Armitage JO, et al. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. Hum Pathol 1999; 30:263.</a></li><li><a class="nounderline abstract_t">Jerusalem GH, Beguin YP. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002; 3:56.</a></li><li><a class="nounderline abstract_t">Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107:175.</a></li><li><a class="nounderline abstract_t">Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101:3875.</a></li><li><a class="nounderline abstract_t">Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16:473.</a></li><li><a class="nounderline abstract_t">Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol 2015; 33:151.</a></li><li><a class="nounderline abstract_t">Alderuccio JP, Reis IM, Koff JL, et al. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 2023; 141:1888.</a></li><li><a class="nounderline abstract_t">Ngan BY, Warnke RA, Wilson M, et al. Monocytoid B-cell lymphoma: a study of 36 cases. Hum Pathol 1991; 22:409.</a></li><li><a class="nounderline abstract_t">Shin SS, Sheibani K, Fishleder A, et al. Monocytoid B-cell lymphoma in patients with Sjögren's syndrome: a clinicopathologic study of 13 patients. Hum Pathol 1991; 22:422.</a></li><li><a class="nounderline abstract_t">Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31:565.</a></li><li><a class="nounderline abstract_t">Zucca E, Conconi A, Martinelli G, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol 2017; 35:1905.</a></li><li><a class="nounderline abstract_t">Merli M, Rattotti S, Spina M, et al. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. J Clin Oncol 2022; 40:4060.</a></li><li><a class="nounderline abstract_t">Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014; 32:3096.</a></li><li><a class="nounderline abstract_t">Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 2016; 173:867.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381:1203.</a></li><li><a class="nounderline abstract_t">Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123:2944.</a></li><li><a class="nounderline abstract_t">Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol 2019; 37:984.</a></li><li><a class="nounderline abstract_t">Alderuccio JP, Arcaini L, Watkins MP, et al. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv 2022; 6:2035.</a></li><li><a class="nounderline abstract_t">Samaniego F, Hagemeister F, Romaguera JE, et al. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 2015; 169:814.</a></li><li><a class="nounderline abstract_t">Khashab T, Hagemeister F, Romaguera JE, et al. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 2019; 185:670.</a></li><li><a class="nounderline abstract_t">Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009; 145:741.</a></li><li><a class="nounderline abstract_t">Luminari S, Merli M, Rattotti S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood 2019; 134:798.</a></li><li><a class="nounderline abstract_t">Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. Am J Hematol 2019; 94:658.</a></li><li><a class="nounderline abstract_t">Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129:2224.</a></li><li><a class="nounderline abstract_t">Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 2020; 4:5773.</a></li><li class="breakAll">Update on ibrutinib U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications. Abbvie. April 6, 2023. Available at: https://news.abbvie.com/news/press-releases/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm (Accessed on April 14, 2023).</li><li><a class="nounderline abstract_t">Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clin Cancer Res 2021; 27:6323.</a></li><li><a class="nounderline abstract_t">Phillips T, Chan H, Tam CS, et al. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2022; 6:3472.</a></li><li class="breakAll">Zanubrutinib capsules. United States prescribing information. Revised September 2021. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213217s005lbl.pdf (Accessed on September 15, 2021).</li><li><a class="nounderline abstract_t">Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15:1311.</a></li><li><a class="nounderline abstract_t">Kiesewetter B, Willenbacher E, Willenbacher W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood 2017; 129:383.</a></li><li><a class="nounderline abstract_t">Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019; 37:1188.</a></li><li><a class="nounderline abstract_t">Avivi I, Arcaini L, Ferretti VV, et al. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. Br J Haematol 2018; 182:807.</a></li><li><a class="nounderline abstract_t">Li L, Bierman P, Vose J, et al. High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11:253.</a></li><li><a class="nounderline abstract_t">Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45:315.</a></li><li><a class="nounderline abstract_t">Nathwani BN, Drachenberg MR, Hernandez AM, et al. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). Semin Hematol 1999; 36:128.</a></li><li><a class="nounderline abstract_t">Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17:2486.</a></li><li><a class="nounderline abstract_t">Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 48:162.</a></li><li><a class="nounderline abstract_t">Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 27:762.</a></li><li><a class="nounderline abstract_t">Starr AG, Caimi PF, Fu P, et al. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Br J Haematol 2016; 175:275.</a></li><li><a class="nounderline abstract_t">Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 2013; 119:99.</a></li><li><a class="nounderline abstract_t">Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950.</a></li><li><a class="nounderline abstract_t">Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006; 85:781.</a></li></ol></div><div id="topicVersionRevision">Topic 113327 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468179" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27335277" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The genetics of nodal marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362442" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530156" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24417667" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12657939" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Marginal zone B-cell lymphoma in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813646" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2502907" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17233821" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20009002" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759529" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9888704" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary nodal marginal zone lymphomas of splenic and MALT type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29556019" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10088543" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141957" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721817" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531812" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Utility of FDG-PET scanning in lymphoma by WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668266" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25407794" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735908" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2032691" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Monocytoid B-cell lymphoma: a study of 36 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1851718" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Monocytoid B-cell lymphoma in patients with Sjögren's syndrome: a clinicopathologic study of 13 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23295789" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28355112" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714311" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154829" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970533" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433739" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24591201" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811293" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35196377" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828695" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30820940" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344412" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31292118" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916801" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167659" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33227125" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33227125" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34526366" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35390135" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35390135" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439689" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879257" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30897038" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29984825" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658651" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101717" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319381" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561313" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405665" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766579" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27443247" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22736411" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706860" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847665" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
